Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
|Articles|April 18, 2017
New products, advancements in dry eye
David Kading, OD, FAAO, FCLSA, discusses new products, studies, and patient education available to help combat dry eye disease.
Advertisement
The views expressed here belong to the author. They do not necessarily represent the views of Optometry Times or UBM Medica.
David Kading, OD, FAAO, FCLSA, discusses new products, studies, and patient education available to help combat dry eye disease.
Advertisement
Related to this article
Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.
Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.
Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.
Coats explains how neurotrophic keratitis, Demodex blepharitis, cosmetic habits, and mucus fishing complicate dry eye disease.
Ashraf Ahmad, MD, explains what's driving rising dry eye rates and why eyelid evaluation is often overlooked.
Ashraf Ahmad, MD, explains what tear breakup time testing shows and why results vary between clinic visits.
Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Demodex tied to worse MGD as dry eye questionnaires miss blepharitis
2
AAOpt 2026: A practical guide to pediatric retina
3
AAOpt 2026: The real-world impact of treatment switch to latanoprostene bunod
4
AAOpt 2026: GLP-1RAs and ocular health
5